Literature DB >> 9777817

Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

R A Preston1, B J Materson, D J Reda, D W Williams, R J Hamburger, W C Cushman, R J Anderson.   

Abstract

CONTEXT: Renin profiling and age-race subgroup may help select single-drug therapy for stage 1 and stage 2 hypertension.
OBJECTIVE: To compare the plasma renin profiling and age-race subgroup methods as predictors of response to single-drug therapy in men with stage 1 and 2 hypertension as defined by the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
DESIGN: The Veterans Affairs Cooperative Study on Single-Drug Therapy of Hypertension, a randomized controlled trial.
SETTING: Fifteen Veterans Affairs hypertension centers. PATIENTS: A total of 1105 ambulatory men with entry diastolic blood pressure (DBP) of 95 to 109 mm Hg, of whom 1031 had valid plasma and urine samples for renin profiling.
INTERVENTIONS: Randomization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem (sustained release), or prazosin. MAIN OUTCOME MEASURE: Treatment response as assessed by percentage achieving goal DBP (<90 mm Hg) in response to a single drug that corresponded to patients' renin profile vs a single drug that corresponded to patients' age-race subgroup.
RESULTS: Clonidine and diltiazem had consistent response rates regardless of renin profile (76%, 67%, and 80% for low, medium, and high renin, respectively, for clonidine and 83%, 82%, and 83%, respectively, for diltiazem for patients with baseline DBP of 95-99 mm Hg). Hydrochlorothiazide and prazosin were best in low- and medium-renin profiles; captopril was best in medium- and high-renin profiles (low-, medium-, and high-renin response rates were 82%, 78%, and 14%, respectively, for hydrochlorothiazide; 88%, 67%, and 40%, respectively, for prazosin; and 51%, 83%, and 100%, respectively, for captopril for patients with baseline DBP of 95-99 mm Hg). Response rates for patients with baseline DBP of 95 to 99 mm Hg by age-race subgroup ranged from 70% for clonidine to 90% for prazosin for younger black men, from 50% for captopril to 97% for diltiazem for older black men, from 70% for hydrochlorothiazide to 92% for atenolol for younger white men, and from 84% for hydrochlorothiazide to 95% for diltiazem for older white men. Patients with a correct treatment for their renin profile but incorrect for age-race subgroup had a response rate of 58.7%; patients with an incorrect treatment for their renin profile but correct for age-race subgroup had a response rate of 63.1% (P = .30). After controlling for DBP and interactions with treatment group, age-race subgroup (P<.001) significantly predicted response to single-drug therapy, whereas renin profile was of borderline significance (P= .05).
CONCLUSIONS: In these men with stage 1 and stage 2 hypertension, therapeutic responses were consistent with baseline renin profile, but age-race subgroup was a better predictor of response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777817     DOI: 10.1001/jama.280.13.1168

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  46 in total

Review 1.  Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure.

Authors:  J E Scoble
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

Review 2.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 3.  Use of gene markers to guide antihypertensive therapy.

Authors:  S T Turner; G L Schwartz; A B Chapman; E Boerwinkle
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 4.  Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Authors:  Hedi Schelleman; Bruno H Ch Stricker; Anthonius De Boer; Abraham A Kroon; Monique W M Verschuren; Cornelia M Van Duijn; Bruce M Psaty; Olaf H Klungel
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

Review 6.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 7.  Personalized medicine for high blood pressure.

Authors:  Stephen T Turner; Gary L Schwartz; Eric Boerwinkle
Journal:  Hypertension       Date:  2007-04-30       Impact factor: 10.190

Review 8.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

9.  Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

Authors:  Caitrin W McDonough; Oyunbileg Magvanjav; Ana C C Sá; Nihal M El Rouby; Chintan Dave; Amelia N Deitchman; Marina Kawaguchi-Suzuki; Wenbin Mei; Yong Shen; Ravi Shankar Prasad Singh; Mohamed Solayman; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Amy Webb; Steven E Scherer; Wolfgang Sadee; Stephen T Turner; Rhonda M Cooper-DeHoff; Yan Gong; Julie A Johnson
Journal:  Circ Genom Precis Med       Date:  2018-04

10.  Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals.

Authors:  Taisei Kobayashi; Thomas J Glorioso; Ehrin J Armstrong; Thomas M Maddox; Mary E Plomondon; Gary K Grunwald; Steven M Bradley; Thomas T Tsai; Stephen W Waldo; Sunil V Rao; Subhash Banerjee; Brahmajee K Nallamothu; Deepak L Bhatt; A Garvey Rene; Robert L Wilensky; Peter W Groeneveld; Jay Giri
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.